Xi'an Faithful BioTech Co., Ltd. is selling Semaglutide Raw Powder. Please feel free to contact us if you have any purchase needs.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
I. Product Essence and Core Value: From Molecular Characteristics to Clinical Applications
Semaglutide raw material powder is the core active pharmaceutical ingredient (API) for preparing various semaglutide formulations. Its chemical formula is C₁₈₇H₂₉₁N₄₅O₅₉, with a molecular weight of 4113.58 g/mol, classifying it as a structurally modified long-chain polypeptide compound. Its core value stems from the precise modification of natural GLP-1, exhibiting 94% sequence homology with endogenous human GLP-1. Breakthrough efficacy is achieved through three major structural optimizations.
First, replacing alanine (Ala) at position 8 with the non-natural amino acid α-aminoisobutyric acid (Aib) effectively resists degradation by dipeptidyl peptidase-4 (DPP-4), extending the in vivo half-life. Second, linking a C18 fatty acid chain to the γGlu-2xOEG linker at position 26 (lys) enhances its binding affinity to plasma albumin, extending the half-life to 7 days. Finally, replacing lysine (Arg) at position 34 prevents fatty acid chain misalignment and improves molecular stability. These modifications preserve the physiological activity of GLP-1 while addressing the clinical challenge of the short half-life (only 1-2 minutes) of natural GLP-1.
In clinical applications, semaglutide raw material powder formulations cover multiple indications: not only for glycemic control in patients with type 2 diabetes, but also for reducing the risk of adverse events in diabetic patients with cardiovascular disease or chronic kidney disease. It has also become a first-line product for obesity treatment, suitable for adult patients with a BMI ≥ 30 kg/m² or a BMI ≥ 27 kg/m² with weight-related comorbidities. With the advancement of clinical research, its application potential in areas such as non-alcoholic fatty liver disease and obstructive sleep apnea is gradually emerging, further amplifying the market demand for the raw material powder.
II. Production Process: Scalable Breakthrough of High-Barrier Technologies
The production of semaglutide raw material powder belongs to the high-barrier field of peptide synthesis. The core challenges lie in the efficient synthesis of long-chain peptides, precise control of complex modifications, and high-purity purification. Currently, the mainstream approach is a semi-synthetic process of "recombinant expression + chemical modification," while some companies are exploring solid-phase synthesis (SPPS) and fermentation routes. The cost and production capacity of different technological paths vary significantly.
(I) Mainstream Process Route: Modular Production Architecture
In commercial production, the preparation of Semaglutide raw material powder is typically broken down into four core modules, forming a standardized production process: First, the Semaglutide precursor is recombinantly expressed using genetically engineered Saccharomyces cerevisiae. During the fermentation stage, the composition of the culture medium (25 g/L glucose + complex nitrogen source) and fermentation parameters need to be controlled to increase the concentration of biomass and the expression level of the precursor. Currently, the industry's advanced level can achieve a single batch precursor yield of 7.4 kg; Second, the tetrapeptide terminal extension fragment is prepared using a solid-phase synthesis method, solving the problem that non-natural amino acid Aib cannot be synthesized through recombinant expression; Third, C18 fatty acid linkers are synthesized in a solid-phase manner, avoiding purification and precipitation problems caused by the hydrophobicity of the linker by precisely controlling the reaction conditions; Fourth, the precursor, tetrapeptide fragment, and fatty acid linker are assembled through a condensation coupling reaction, and then purified by reversed-phase high-performance liquid chromatography (RP-HPLC) and freeze-dried to obtain the finished raw material powder.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
III. Market Landscape: Global Demand Explosion and Domestic Capacity Breakthrough
Benefiting from the global boom in pharmaceutical formulations, the market demand for semaglutide raw material powder has experienced explosive growth. In 2024, Novo Nordisk's semaglutide series product sales approached $30 billion, and in Q3 2025, sales reached $25.462 billion, consistently indicating a supply shortage. Global demand for semaglutide raw materials is projected to exceed 50 tons in 2025. This significant supply gap is driving raw material companies to accelerate capacity expansion, resulting in a competitive market characterized by "original research dominance and the rise of domestic products."
(I) Global Competitive Tiers and Capacity Layout
The first tier consists of raw material suppliers: Novo Nordisk, as a raw material company, controls core technologies and the high-end market, but its capacity is limited. Nortech Biotech, with its 5-ton annual capacity at its Lianyungang base (to be operational in 2025) and its Wuhan base expansion plan, is expected to have a total capacity exceeding 10 tons. Its single-batch output and yield rate are industry-leading, and it has established stable partnerships with European and American companies such as Krka and Teva, covering 20% of the global market share. The second tier comprises domestic companies rapidly expanding their production capacity. Puli Pharmaceutical, with a trial production capacity of 12 tons/year, has become the "capacity king" and plans to expand to 50 tons/year. Hanyu Pharmaceutical and Shengnuo Biotechnology plan annual capacities of 5-10 tons and over 10 tons respectively, forming the backbone of the industry. The third tier consists of small and medium-sized entrants, such as Borui Pharmaceutical and Sinopharm, which have established production capacities in the hundreds of kilograms range, focusing on intermediates or niche customer needs.
CDMO companies have become an important supplementary force. WuXi AppTec plans a 100,000-liter reactor volume, and Kairui Pharmaceutical will reach a capacity of 44,000 liters by the end of the year. Leveraging their vast infrastructure and customer networks, they undertake customized production needs from raw material companies. In 2024, domestic GLP-1 raw material CDMO orders exceeded 290 million yuan.
(II) Price Fluctuations and Market Demand Drivers
From the end of 2025, a price storm in the GLP-1 field reshaped the market logic: Eli Lilly's Tirzepatide saw a monthly treatment cost reduction of over 80% after being included in medical insurance, forcing Novo Nordisk to follow suit with price cuts. The downward pressure on the price of Semaglutide formulations was transmitted to the raw material end. In the US market, medical insurance negotiations reduced the monthly treatment cost of GLP-1 to around $350, demonstrating a global price linkage effect and forcing raw material companies to maintain profitability through cost reduction through technology.
On the demand side, in addition to the traditional blood sugar and weight loss areas, emerging markets and the expansion of indications have become new growth engines. Emerging markets such as India and Brazil have achieved localized penetration through generic drug collaborations, reducing the price of generic products to 20% of the original price, driving the proportion of raw material demand to 35%; the approval of new indications such as cardiovascular and kidney protection further opens up long-term growth potential for raw material powders.
IV. Industry Trends and Challenges: Competitive Restructuring Under Technological Iteration
(I) Core Development Trends
Accelerated technological iteration is reducing costs and increasing efficiency. Synthetic biology and green processes are becoming mainstream directions. Companies are reducing solvent use through a combination of fermentation and chemical modification. Electrostatic spray drying technology is expected to achieve breakthroughs in production capacity of tens of tons. The integration of the industrial chain is intensifying. Companies such as Livzon Pharmaceutical Group and Jiuyuan Gene are simultaneously developing raw materials and formulations, shifting from competition based on single products to competition based on the entire industrial chain. Companies such as Hanyu Pharmaceutical are adopting a multi-product co-production strategy to improve capacity flexibility and cope with internal competition in the GLP-1 market.
Globalization is deepening. Domestic companies are gradually penetrating the high-end markets in Europe and the United States by signing strategic cooperation agreements with overseas generic product companies, while also expanding into emerging markets such as the Middle East and Africa. It is estimated that by 2025, the overseas revenue of leading companies will account for more than 60%. The expansion of new targets and indications continues. Research on Semaglutide in the fields of nervous system and liver diseases is progressing, which will further open up the demand space for raw material powder.
(II) Core Challenges in the Industry
The risk of overcapacity is becoming apparent. Domestic companies have planned production capacities exceeding 70 tons, far exceeding the current global demand of 50 tons. After the concentrated release of this capacity in 2026-2027, market competition will shift from capacity competition to quality and cost competition. Downward pressure on prices continues. Significant reductions in raw material prices are squeezing the profit margins of imitation products. Domestic raw material companies need to reduce unit costs below the industry average through technological innovation to maintain profitability. Patent and technological barriers remain. Core patents held by raw material companies in areas such as molecular modification and process optimization have not yet fully expired. Domestic companies need to overcome patent restrictions and build independent technological systems.
Conclusion
The semaglutide raw material powder industry is at a critical stage of technological breakthroughs and market restructuring, with a strong resonance between explosive global demand and the rise of domestic production capacity. In the future, companies with large-scale production capacity, core technological barriers, and global compliance capabilities will stand out, and industry competition will shift from a "capacity race" to a "value race." With continuous technological iteration and expanded clinical applications, semaglutide raw material powder will not only promote the sustainable development of the GLP-1 field but also provide an important model for the upgrading of the peptide raw material industry, ultimately achieving the industry goal of "high quality and accessibility," benefiting more patients with diabetes and obesity worldwide.
As a provider of premium Semaglutide CAS 910463-68-2, Xi'an Faithful BioTech Co., Ltd. leverages state-of-the-art production technology and rigorous quality assurance to meet international pharmaceutical requirements. Our dedication to superior quality, cost-effective pricing, and tailored technical support has made us the preferred collaborator for healthcare professionals and researchers worldwide. To obtain detailed specifications and application guidance for our Semaglutide Powder, contact our technical team at sales4@faithfulbio.com and explore how our offerings can enhance your product formulations.